Delcath Systems Set to Join Russell Microcap® Index
June 08 2021 - 8:00AM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of rare primary and metastatic
cancers of the liver, is set to join the Russell Microcap® Index at
the conclusion of the 2021 Russell indexes annual reconstitution
effect after the US market opens on June 28, according to a
preliminary list of additions posted June 4.
Membership in the Russell Microcap® Index, which remains in
place for one year, means automatic inclusion in the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
“Inclusion in this index is an important milestone for our
company, one that we believe will increase our exposure within the
investment community and provide us with a meaningful opportunity
to reach new investors, particularly those who use the Russell
indexes to benchmark their portfolios,” said Gerard Michel, CEO of
Delcath.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell’s US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap®
Index and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional
oncology company focused on the treatment of primary and metastatic
liver cancers. The company’s proprietary percutaneous hepatic
perfusion (PHP) system is designed to administer high-dose
chemotherapy to the liver while controlling systemic exposure and
associated side effects. In the United States, the PHP system is
being developed under the tradename HEPZATO KIT (melphalan
hydrochloride for injection/hepatic delivery system), or HEPZATO,
and is considered a combination drug and device product regulated
by the United States Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a
Class IIb medical device and is approved for sale under the trade
name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT,
where it has been used at major medical centers to treat a wide
range of cancers of the liver. CHEMOSAT is being marketed under an
exclusive licensing agreement with medac GmbH, a privately held
multi-national pharmaceutical company headquartered in Germany that
specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
About FTSE Russell
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of indexes
that measure and benchmark markets and asset classes in more than
70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $17.9 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly owned by London Stock
Exchange Group. For more information, visit
www.ftserussell.com.
Contact
Delcath Investor RelationsEmail:
investorrelations@delcath.com
Hayden IRJames
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Oct 2023 to Oct 2024